NCT03589144 (SPECTROSPOT) is a clinical trial in Adrenal Hyperplasia, Congenital, sponsored by Assistance Publique - Hôpitaux de Paris.

Who is sponsoring NCT03589144?

NCT03589144 is sponsored by Assistance Publique - Hôpitaux de Paris.

What condition does NCT03589144 study?

NCT03589144 studies Adrenal Hyperplasia, Congenital.

Is NCT03589144 still recruiting?

NCT03589144 is currently completed. Last updated 28 October 2021.

Last reviewed 2021-10-28 · How we verify

NCT03589144: SPECTROSPOT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

LC-MS / MS Adrenal Steroids Assayed on Dried Blot Spot for the Congenital Adrenal Hyperplasia Neonatal Screening (SPECTROSPOT)

Completed Last updated 28 October 2021

What this trial tests

trial in Adrenal Hyperplasia, Congenital in 132 participants. Completed in 29 April 2020.

Timeline

11 February 2019

Primary endpoint
29 April 2020

29 April 2020

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Status	Completed
Study type	OBSERVATIONAL
Enrollment	132
Start date	11 February 2019
Primary completion	29 April 2020
Estimated completion	29 April 2020
Sites	1 location across France

Conditions studied

Adrenal Hyperplasia, Congenital — all drugs for Adrenal Hyperplasia, Congenital →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

Adults 48 Hours to 120 Hours, any sex, with Adrenal Hyperplasia, Congenital. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research uses the Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS / MS) technique on dried blot spot samples for the neonatal screening of congenital adrenal hyperplasia. The main objective of this study is to demonstrate that this technique allow dosage of adrenal steroids on dried blot spot samples as efficiently and with the same sensitivity than the current technic on a cohort of 132 newborns aged 2 to 5 days, with a gestational age greater than or equal to 30 weeks of amenorrhea.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03589144 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
Last refreshed: 28 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03589144.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing